Research and development and new product development in collaboration with customers and relevant institutions
First written in FY2016. 25 of 33 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Total research and development expenses incurred during the fiscal year amounted to ¥371 million. One type of powered air-purifying respirator with particulate protection and 2 types with gas protection passed national certification testing. One type obtained CE certification (Europe) and 3 types obtained LA certification (China).」
The company spent ¥371 million on research and development and reported national certification and other approvals for powered air-purifying respirators, canisters for gas respirators, and products conforming to overseas standards. - FY2025AdvancedAnnual report
「Total research and development expenses incurred during the fiscal year amounted to ¥369 million. Three types of powered air-purifying respirators with gas protection functions passed national certification testing. Two types of replaceable-filter particulate respirators, 1 type of gas respirator, and 4 types of canisters for gas respirators passed national certification testing. Two types obtained LA certification.」
The company spent ¥369 million on research and development and reported specific certification and standards approvals for powered air-purifying respirators, particulate and gas respirators, canisters, and products conforming to overseas standards. - FY2025-H1RestatedAnnual report
「Total research and development expenses for the current interim accounting period amounted to ¥178 million.」
The company continued research and development activities, and research and development expenses for the current interim accounting period amounted to ¥178 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2024-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥278 million.」
The company continued research and development activities, and research and development expenses for the cumulative third quarter amounted to ¥278 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2024-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter amounted to ¥187 million.」
The company continued research and development activities, and research and development expenses for the cumulative second quarter amounted to ¥187 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2024-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter amounted to ¥90 million.」
The company continued research and development activities, and research and development expenses for the cumulative first quarter amounted to ¥90 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2023-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥258 million.」
The company continued research and development activities, and research and development expenses for the cumulative third quarter amounted to ¥258 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2023-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter amounted to ¥170 million.」
The company continued research and development activities, and research and development expenses for the cumulative second quarter amounted to ¥170 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥77 million.」
The company continued research and development activities, and research and development expenses for the cumulative first quarter amounted to ¥77 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2022AdvancedAnnual report
「Total research and development expenses incurred during the fiscal year amounted to ¥390 million. Three types of powered air-purifying respirators passed national certification testing. Ten types of replaceable-filter particulate respirators and 1 type of gas respirator passed national certification testing. Two types of canisters for air-supplied gas respirators passed national certification testing. Three types obtained European certification, 2 types obtained NIOSH certification, and 5 types obtained LA certification.」
The company spent ¥390 million on research and development and reported specific certification and standards approvals for powered air-purifying respirators, particulate and gas respirators, canisters, and products conforming to overseas standards. - FY2022-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥278 million.」
The company continued research and development activities, and research and development expenses for the cumulative third quarter amounted to ¥278 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2022-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter amounted to ¥179 million.」
The company continued research and development activities, and research and development expenses for the cumulative second quarter amounted to ¥179 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2022-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter amounted to ¥85 million.」
The company continued research and development activities, and research and development expenses for the cumulative first quarter amounted to ¥85 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2021AdvancedAnnual report
「Total research and development expenses incurred during the fiscal year amounted to ¥384 million. Four types of powered air-purifying respirators passed national certification testing. Four types of disposable particulate respirators, 19 types of replaceable-filter particulate respirators, and 3 types of gas respirators passed national certification testing. Four types obtained European certification and 13 types obtained Korean certification.」
The company spent ¥384 million on research and development and reported specific certification and standards approvals for powered air-purifying respirators, particulate and gas respirators, canisters, and products conforming to overseas standards. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥259 million.」
The company continued research and development activities, and research and development expenses for the cumulative third quarter amounted to ¥259 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2021-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter amounted to ¥171 million.」
The company continued research and development activities, and research and development expenses for the cumulative second quarter amounted to ¥171 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter amounted to ¥71 million.」
The company continued research and development activities, and research and development expenses for the cumulative first quarter amounted to ¥71 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2020AdvancedAnnual report
「Total research and development expenses incurred during the fiscal year amounted to ¥379 million. Two types of powered air-purifying respirators passed national certification testing. Two types of disposable particulate respirators, 3 types of replaceable-filter particulate respirators, and 1 type of gas respirator passed national certification testing. Two types of canisters for air-supplied gas respirators passed national certification testing. One type passed European standards and 7 types passed Korean standards.」
The company spent ¥379 million on research and development and reported specific certification and standards approvals for powered air-purifying respirators, particulate and gas respirators, canisters, and products conforming to overseas standards. - FY2020-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥272 million.」
The company continued research and development activities, and research and development expenses for the cumulative third quarter amounted to ¥272 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2020-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter amounted to ¥194 million.」
The company continued research and development activities, and research and development expenses for the cumulative second quarter amounted to ¥194 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2020-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter amounted to ¥93 million.」
The company continued research and development activities, and research and development expenses for the cumulative first quarter amounted to ¥93 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2019AdvancedAnnual report
「Total research and development expenses incurred during the fiscal year amounted to ¥373 million. Two types of powered air-purifying respirators passed national certification testing. Seven types of disposable particulate respirators, 5 types of replaceable-filter particulate respirators, and 2 types of gas respirators passed national certification testing. Six types passed European standards and 12 types passed Korean standards.」
The company spent ¥373 million on research and development and reported numerous certification and standards approvals for powered air-purifying respirators, particulate and gas respirators, canisters, and products conforming to overseas standards. - FY2019-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥279 million.」
The company continued research and development activities, and research and development expenses for the cumulative third quarter amounted to ¥279 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2019-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter amounted to ¥184 million.」
The company continued research and development activities, and research and development expenses for the cumulative second quarter amounted to ¥184 million. No specific progress, such as completion of new products or standards approvals, was reported. - FY2019-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter amounted to ¥102 million.」
The company continued research and development activities, and research and development expenses for the cumulative first quarter amounted to ¥102 million. This filing does not describe specific progress, such as completion of new products or standards approvals. - FY2018AdvancedAnnual report
「Total research and development expenses incurred during the fiscal year amounted to ¥388 million. One type of powered air-purifying respirator passed national certification testing. Two types passed European standards and 2 types passed Chinese standards. One type of powered air-purifying respirator also passed Korean standards.」
The company spent ¥388 million on research and development and reported certification and standards approvals for powered air-purifying respirators, particulate and gas respirators, and products conforming to European, Chinese, and Korean standards. Specific progress in product development and standards compliance can be confirmed. - FY2018-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥290 million.」
The company continued research and development, and research and development expenses for the cumulative third quarter amounted to ¥290 million. No specific results for completed new product development were reported. - FY2018-Q2RestatedAnnual report
「Total research and development expenses for the six months ended the second quarter were ¥201 million.」
The company continued research and development, and research and development expenses for the cumulative second quarter amounted to ¥201 million. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter were ¥89 million.」
The company continued research and development, and research and development expenses for the cumulative first quarter amounted to ¥89 million. - FY2017-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter amounted to ¥310 million.」
The company continued research and development related to new product development and other areas, and research and development expenses for the cumulative third quarter amounted to ¥310 million. - FY2017-Q2RestatedAnnual report
「Selling, general and administrative expenses increased 6.1% year on year to ¥1,465 million, mainly due to higher research and development expenses associated with new product development and higher expenses related to sales expansion activities from the beginning of the period. Total research and development expenses for the cumulative second quarter amounted to ¥213 million.」
The company continued to focus on new product development, and research and development expenses for the cumulative second quarter amounted to ¥213 million. - FY2017-Q1RestatedAnnual report
「Selling, general and administrative expenses increased 6.6% year on year to ¥715 million, mainly due to higher expenses associated with the company's focus on new product development. Total research and development expenses for the cumulative first quarter amounted to ¥102 million.」
The company continued to focus on new product development, and research and development expenses for the first quarter amounted to ¥102 million. There was no change to the existing research and development policy of collaborating with customers and relevant institutions and developing new products. - FY2016First statedAnnual report
「For research and development, the company formulates plans focused mainly on research topics that have become urgent from a business strategy perspective, and develops products by incorporating customer feedback with the cooperation of relevant institutions. The company also works to improve evaluation standards for protective equipment, actively presenting its research results at academic conferences and other venues and contributing to improvements in industrial safety and health. Total research and development expenses incurred during the fiscal year amounted to ¥412 million.」
Research and development expenses for the fiscal year amounted to ¥412 million. The company reported multiple national certification approvals for powered air-purifying respirators, particulate and gas respirators, and canisters.